By vgreene, 29 April, 2020 No significant difference in 28-day in-hospital mortality (13% in both groups) or 60-day in-hospital mortality (19% IVIG, 14% non-IVIG); IVIG group had longer length of stay (23.5 vs 16 days) and longer dz duration (31 vs 23 days)
By vgreene, 29 April, 2020 Retrospective study; 325 hospitalized pts (mean age, 58y) w/ confirmed SARS-CoV-2 (68% severe, 32% critical); 174 pts received IVIG 0.1-0.5 g/kg daily x5-15 days, 151 pts received SOC only; IVIG pts had more severe dz (higher APACHE II, SOFA scores, O2 ne
By vgreene, 29 April, 2020 Proposed mechanism: reduces inflammatory response by blunting catecholamine effects on cytokine production
By vgreene, 29 April, 2020 Baricitinib Therapy in COVID-19: A Pilot Study of Safety and Clinical Impact; access J Infect article
By vgreene, 29 April, 2020 Favipiravir vs Arbidol for COVID-19: A Randomized Controlled Trial [nid:217556]